Loading...
NPI 1891770806 · Charleston, WV · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Laboratory Corporation Of America Holdings is a clinical medical laboratory provider located in Charleston, West Virginia. This profile covers 61 Medicare and 203 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Laboratory Corporation Of America Holdings |
| Address | 120 Hills Plz |
| City | Charleston |
| State | WV |
| ZIP | 25387 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | December 13, 2005 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $220M |
| Medicare | $1.9M |
This provider’s revenue is overwhelmingly Medicaid‑driven: lifetime Medicare revenue is $1.9M versus lifetime Medicaid revenue of $220M, indicating Medicaid is by far the primary payer and the provider operates with a Medicaid‑heavy payer mix. Medicare activity exists but is small relative to Medicaid, so network and contracting engagement will likely be dominated by state Medicaid relationships.
Medicare revenue is highly concentrated: the precomputed top three Medicare codes account for 80.9% of Medicare revenue, led by 87999 (47.8%), followed by G0145 (23.6%) and 87624 (9.4%). This concentration indicates that a few laboratory services—primarily unspecified microbiology procedures and cervical cytopathology/HPV testing—drive the bulk of the provider’s Medicare billing.
Medicaid revenue is also concentrated in a few test types: the precomputed top three Medicaid codes account for 59.2% of Medicaid revenue, with 87591 and 87491 each contributing 23.1% and 87661 contributing 13.1%. Those three codes show the provider’s Medicaid business is anchored in high-volume sexually transmitted infection (GC/CT) and Trichomonas testing.
The code mix signals a service line focused on high-volume infectious disease and reproductive health diagnostics: high Medicare share for G0145 and 87624 and Medicaid dominance of 87591, 87491, 87661, plus large state volumes for 88175 and multiple NAAT codes (e.g., 87798, 87801), point to laboratory infrastructure optimized for high-throughput NAAT and cytology screening. The presence of U0003 among top Medicaid codes further indicates capability for large-scale SARS‑CoV‑2 molecular testing.
National competitive standing on Medicare is notable for cytology and HPV testing: G0145 ranks #4 of 349 providers nationally (99th percentile, labeled an extreme outlier) and 87624 ranks #6 of 475 (99th percentile, extreme outlier), while G0124 ranks #2 of 530 (100th percentile, extreme outlier). These rank/percentile positions indicate this provider is a major national participant for cervical cytopathology and HPV services, even though its overall Medicare dollars are modest.
State-level competitive standing on Medicaid is dominant across many core tests: the provider ranks #1 in‑state for a long list of high‑revenue codes (including 87591, 87491, 87661, 87798, 88175, 87624 and others) and those codes are repeatedly labeled "extreme outlier" or "notably above typical" in the dataset. This pattern shows the provider functions as a statewide laboratory leader for STI, HPV, cytology, and multiple infectious‑disease panels.
The large share of Medicare revenue billed to 87999 (47.8% of Medicare revenue) suggests a substantial volume of microbiology procedures being reported with an unspecified code. Combined with the provider’s high rankings on more specific cytology/NAAT codes, this indicates a mix of standardized high‑volume panels and a meaningful portion of testing that is billed under catch‑all microbiology reporting, which affects how granularly service mix can be analyzed from claims alone.
The NPI was enumerated on 2005-12-13 (~21 years ago), reflecting long tenure in the market; coupled with top national percentiles on specific Medicare codes and repeated #1 in‑state Medicaid ranks, this suggests an established laboratory with sustained payer relationships and a broad operational footprint across both federal and state programs.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
61 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87999 | Use 87999 to report microbiology procedures that do not have a specific code. | 3,650 | $240 | $880.1K |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under… | 16,740 | $30 | $435.1K |
| 87624 | The lab analyst performs a test to determine the presence of human papillomavirus, or HPV. The provider uses nucleic acid detection for high–risk types and produces a pooled result. | 5,100 | $30 | $173.4K |
| 88175 | The lab analyst performs the technical lab test to analyze a cervical or vaginal cytopathology specimen that a clinician collected in preservative fluid. The test uses automated thin layer… | 2,310 | $30 | $60.1K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 1,740 | $30 | $59.1K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 1,360 | $30 | $46.1K |
| 88112 | Selective cellular enhancement for cytopathology, such as the method of using a liquid–based slide preparation, uses a liquid–based medium to collect samples and preserve cells which can aid in… | 1,140 | $40 | $43.2K |
| 88173 | The lab analyst performs the technical lab test to analyze a cytopathology specimen from a fine needle aspirate and then interprets and reports the results. | 260 | $110 | $27.5K |
| G0124 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, requiring interpretation by physician | 1,050 | $20 | $22K |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | 960 | $20 | $19.2K |
Showing 1–10 of 61
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 61 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
61 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 87999 | 1 | 10 | 3,650 | $240 | $879K |
| G0145 | 1 | 10 | 16,740 | $30 | $434.5K |
| 87624 | 1 | 10 | 5,100 | $30 | $175.4K |
| 88175 | 1 | 10 | 2,310 | $30 | $60.3K |
| 87491 | 1 | 10 | 880 | $30 | $30.2K |
| 88305 | 67 | 80 | 670 | $30 | $23.9K |
| 87591 | 1 | 10 | 690 | $30 | $23.7K |
| G0123 | 1 | 10 | 960 | $20 | $19.1K |
| G0476 | 1 | 10 | 380 | $30 | $12.9K |
| G0124 | 1 | 10 | 530 | $20 | $11K |
Showing 1–10 of 61
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
203 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 1,726,970 | $30 | $50.1M |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 1,723,800 | $30 | $50M |
| 87661 | The lab analyst performs a test for Trichomonas vaginalis using nucleic acid amplified probe technique. | 1,286,500 | $20 | $28.3M |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 536,530 | $40 | $19.9M |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 436,370 | $40 | $19.2M |
| 88175 | The lab analyst performs the technical lab test to analyze a cervical or vaginal cytopathology specimen that a clinician collected in preservative fluid. The test uses automated thin layer… | 946,660 | $20 | $16.1M |
| 87624 | The lab analyst performs a test to determine the presence of human papillomavirus, or HPV. The provider uses nucleic acid detection for high–risk types and produces a pooled result. | 631,400 | $20 | $14.5M |
| 87389 | The lab analyst performs a test to screen for human immunodeficiency virus, called HIV. The test screens for antigens of the HIV 1 virus and antibodies to the HIV 1 and HIV 2 viruses using an… | 127,850 | $40 | $5.4M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 63,590 | $70 | $4.2M |
| 88141 | The physician analyzes and interprets a cervical or vaginal cytopathology specimen, using any reporting system, such as Bethesda or non–Bethesda. This code is for the professional interpretation by… | 159,650 | $10 | $1.9M |
Showing 1–10 of 203
How this provider's Medicaid billing volume and revenue compare to other West Virginia providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. West Virginia median
203 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 1 | 10 | 230 | $40 | $1.9M |
| 87661 | The lab analyst performs a test for Trichomonas vaginalis using nucleic acid amplified probe technique. | 1 | 20 | 270 | $20 | $1.5M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 17 | 20 | 1,050 | $80 | $1.3M |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 1 | 40 | 820 | $30 | $1.2M |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 1 | 40 | 820 | $30 | $1.2M |
| 88175 | The lab analyst performs the technical lab test to analyze a cervical or vaginal cytopathology specimen that a clinician collected in preservative fluid. The test uses automated thin layer… | 1 | 20 | 70 | $20 | $832.7K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 1 | 30 | 180 | $40 | $773.3K |
| 87624 | The lab analyst performs a test to determine the presence of human papillomavirus, or HPV. The provider uses nucleic acid detection for high–risk types and produces a pooled result. | 1 | 20 | 720 | $20 | $721.7K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 17 | 110 | 2,080 | $50 | $537.1K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 19 | 50 | 800 | $70 | $504.4K |
Showing 1–10 of 203
Other providers in the same ZIP code as Laboratory Corporation Of America Holdings, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Elder Aide Services | WV | Home Health Agency | $0 | $15.1M |
| Msrc, LLC | WV | Community/Behavioral Health Agency | $0 | $10.8M |
| Womencare, Inc | WV | Federally Qualified Health Center (FQHC) | $0 | $10.6M |
| Elder Aide Services | WV | Homemaker | $0 | $8.8M |
| Partnership Of African American Churches Inc. | WV | Mental Health Clinic/Center (Including Community Mental Health Center) | $0 | $4.9M |
| Brian Macaulay | WV | Family Medicine Physician | $50.4K | $0 |
| Mark Mcdaniel | WV | Family Medicine Physician | $22.9K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.